Form 13-F position report

PTC THERAPEUTICS INC

Reported by LOOMIS SAYLES & CO L P

PTCT CUSIP 69366J200 Manager CIK 0000312348

Reported 639,579 shares, up 49,205 (8.3%) from the prior quarter.

Reported value -14.0%; share count 8.3% vs. the prior quarter.

Added
% of reported 13F value 0.05% This manager · Q3 2026
Shares 639,579 Quarter-end amount reported
Reported value $41,431,928 Fair value at quarter end
Consecutive quarters held 3 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 61188000
2022-03-31 61441000
2022-06-30 65571000
2022-09-30 81269000
2022-12-31 46807000
2023-03-31 59634000
2023-06-30 43167000
2023-09-30 0
2026-03-31 33629173
2026-06-30 48156807
2026-09-30 41431928

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for PTC THERAPEUTICS INC held by LOOMIS SAYLES & CO L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 639,579 +49,205 (8.3%) 0.05% $41,431,928 2026-11-12
Q2 2026 Added 590,374 +96,771 (19.6%) 0.06% $48,156,807 2026-08-14
Q1 2026 New 493,603 +493,603 (0.0%) 0.05% $33,629,173 2026-05-14
Q3 2023 Reduced 0 -1,061,398 (-100.0%) 0 $0 2023-11-09
Q2 2023 Reduced 1,061,398 -169,684 (-13.8%) 0.07% $43,167,000 2023-08-11
Q1 2023 Added 1,231,082 +4,817 (0.4%) 0.1% $59,634,000 2023-05-11
Q4 2022 Reduced 1,226,265 -392,629 (-24.3%) 0.09% $46,807,000 2023-02-10
Q3 2022 Reduced 1,618,894 -17,941 (-1.1%) 0.16% $81,269,000 2022-11-14
Q2 2022 Reduced 1,636,835 -9,949 (-0.6%) 0.12% $65,571,000 2022-08-05
Q1 2022 Added 1,646,784 +110,561 (7.2%) 0.08% $61,441,000 2022-05-13
Q4 2021 Added 1,536,223 +247,968 (19.2%) 0.07% $61,188,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

431 managers reported PTC THERAPEUTICS INC for Q3 2026.

Managers reporting PTC THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 14,397,317 +432,763 0.01% $932,658,183 9 qtrs
JANUS HENDERSON GROUP PLC Reduced 6,871,205 -322,228 0.19% $445,053,144 1 qtr
STATE STREET CORPORATION Added 5,512,555 +913,603 0.01% $357,079,668 53 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 5,277,697 +1,149,424 0.06% $341,889,211 53 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 4,978,205 +50,094 0.01% $322,488,120 3 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Reduced 3,618,497 -120,630 < 0.01% $234,406,236 3 qtrs
WESTFIELD CAPITAL MANAGEMENT CO LP Added 2,699,340 +743,184 0.57% $174,863,245 2 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 2,147,988 -59,388 < 0.01% $139,173,677 53 qtrs
UBS Group AG Added 1,880,447 +1,618,021 0.02% $121,815,357 48 qtrs
Hood River Capital Management LLC Added 1,756,325 +17,712 0.96% $113,774,734 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 12, 2026
Filing type
13F-HR
Position type
COMMON

Voting authority reported

Sole
626,377
Shared
0
None
13,202

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.